Mood & Emotion (우울조울병)

Korean Society for Affective Disorders (대한우울조울병학회)
권호 표지

Korean Medication Algorithm for Bipolar Disorder 2018 : Medical Comorbidity

한국형 양극성 장애 약물치료 알고리듬 2018 : 신체 질환이 동반되었을 경우

  • Song, Hoo Rim (Department of Psychiatry, Myongji Hospital) ;
  • Bahk, Won-Myong (Department of Psychiatry, College of Medicine, The Catholic University of Korea) ;
  • Yoon, Bo-Hyun (Department of Psychiatry, Naju National Hospital) ;
  • Jon, Duk-In (Department of Psychiatry, Sacred Heart Hospital, Hallym University) ;
  • Seo, Jeong Seok (Department of Psychiatry, School of Medicine, Konkuk University) ;
  • Kim, Won (Department of Psychiatry, Seoul Paik Hospital, College of Medicine, Inje University) ;
  • Lee, Jung Goo (Department of Psychiatry, Haeundae Paik Hospital, College of Medicine, Inje University and Paik Institute for Clinical Research) ;
  • Woo, Young Sup (Department of Psychiatry, College of Medicine, The Catholic University of Korea) ;
  • Jeong, Jong-Hyun (Department of Psychiatry, College of Medicine, The Catholic University of Korea) ;
  • Kim, Moon-Doo (Department of Psychiatry, Jeju National University Hospital) ;
  • Sohn, InKi (Department of Psychiatry, Keyo Hospital, Keyo Medical Foundation) ;
  • Shim, Se-Hoon (Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University) ;
  • Min, Kyung Joon (Department of Psychiatry, College of Medicine, Chung-Ang University)
  • 송후림 (명지병원 정신건강의학과) ;
  • 박원명 (가톨릭대학교 의과대학 정신과학교실) ;
  • 윤보현 (국립나주병원 정신건강의학과) ;
  • 전덕인 (한림대학교 의과대학 성심병원 정신건강의학과) ;
  • 서정석 (건국대학교 의학전문대학원 충주병원 정신건강의학교실) ;
  • 김원 (인제대학교 의과대학 서울백병원 정신건강의학과) ;
  • 이정구 (인제대학교 의과대학 해운대백병원 정신건강의학과 및 백인제기념 임상의학연구소) ;
  • 우영섭 (가톨릭대학교 의과대학 정신과학교실) ;
  • 정종현 (가톨릭대학교 의과대학 정신과학교실) ;
  • 김문두 (제주대학교병원 정신건강의학과) ;
  • 손인기 (계요의료재단 계요병원 정신건강의학과) ;
  • 심세훈 (순천향대학교 의과대학 천안병원 정신건강의학과) ;
  • 민경준 (중앙대학교 의과대학 정신건강의학교실)
  • Received : 2018.10.05
  • Accepted : 2018.10.11
  • Published : 2018.11.30

⟨ Previous Next ⟩

Abstract

Objectives : The fourth revision of Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was performed in 2018, to provide newer guidelines for clinicians. In this section, we examined expert opinions to facilitate clinical decisions relative to treating bipolar disorder with medical comorbidity. Methods : The survey was completed by the review committee, consisting of 61 experienced psychiatrists. This part of the survey constitutes treatment strategies, under major medical comorbidities. The executive committee analyzed results, and discussed the final production of algorithm. Results : Aripiprazole was the first-line medication for bipolar patients with metabolic syndrome, cardiovascular, hepatic, renal, and cerebrovascular comorbidities. Ziprasidone also was recommended as the first-line medication in case of metabolic syndrome. Lithium also was regarded as the first-line medication, in case of hepatic problems. Valproate also was considered as the first-line medication, in case of cerebrovascular problems. Conclusion : This study provided the most recent consensus among experts, for treatment of bipolar disorder with physical problems.

Keywords

Acknowledgement

Supported by : 대한우울.조울병학회, 대한정신약물학회

References

  1. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002;68:167-181. https://doi.org/10.1016/S0165-0327(01)00377-9
  2. McIntyre RS, Rosenbluth M, Ramasubbu R, Bond DJ, Taylor VH, Beaulieu S, et al. Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder. Ann Clin Psychiatry 2012;24:163-169.
  3. Gurpegui M, Martinez-Ortega JM, Gutierrez-Rojas L, Rivero J, Rojas C, Jurado D. Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuropsychopharmacol Biol Psychiatry 2012;37:169-175. https://doi.org/10.1016/j.pnpbp.2012.01.014
  4. Hohmann E, Brand JC, Rossi MJ, Lubowitz JH. Expert Opinion Is Necessary: Delphi Panel Methodology Facilitates a Scientific Approach to Consensus. Arthroscopy 2018;34:349-351. https://doi.org/10.1016/j.arthro.2017.11.022
  5. Salvador-Carulla L, Lukersmith S, Sullivan W. From the EBM pyramid to the Greek temple: a new conceptual approach to Guidelines as implementation tools in mental health. Epidemiol Psychiatr Sci 2017;26:105-114. https://doi.org/10.1017/S2045796016000767
  6. Kahn DA, Sachs GS, Printz DJ, Carpenter D, Docherty JP, Ross R. Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines. J Psychiatr Pract 2000;6:197-211. https://doi.org/10.1097/00131746-200007000-00004
  7. Woo YS, Lee JG, Jeong JH, Kim MD, Sohn I, Shim SH, et al. Korean Medication Algorithm Project for Bipolar Disorder: third revision. Neuropsychiatr Dis Treat 2015;11:493-506.
  8. Reynolds GP, McGowan OO. Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2017;31:1430-1436. https://doi.org/10.1177/0269881117722987
  9. Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 2004;24:212-228. https://doi.org/10.1592/phco.24.2.212.33145
  10. Kemp DE, Eudicone JM, McQuade RD, Chambers JS, Baker RA. Metabolic syndrome and its potential effect on treatment response to aripiprazole: a post hoc analysis of the stabilization phase of a longterm, double-blind study in patients with bipolar disorder (CN138-010). J Clin Psychopharmacol 2010;30:631-634. https://doi.org/10.1097/JCP.0b013e3181f0569f
  11. Gupta S, Masand P. Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders. Ann Clin Psychiatry 2004;16:155-166. https://doi.org/10.1080/10401230490487007
  12. Daniel DG. Tolerability of ziprasidone: an expanding perspective. J Clin Psychiatry 2003;64 Suppl 19:40-49. https://doi.org/10.4088/JCP.v64n0109
  13. Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf 2015;14:73-96. https://doi.org/10.1517/14740338.2015.974549
  14. Young SL, Taylor M, Lawrie SM. "First do no harm." A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol 2015;29:353-362. https://doi.org/10.1177/0269881114562090
  15. Tondo L, Abramowicz M, Alda M, Bauer M, Bocchetta A, Bolzani L, et al. Long-term lithium treatment in bipolar disorder: effects on glomerular filtration rate and other metabolic parameters. Int J Bipolar Disord 2017;5:27. https://doi.org/10.1186/s40345-017-0096-2
  16. Peselow ED, Clevenger S, IsHak WW. Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study. Int Clin Psychopharmacol 2016;31:218-223. https://doi.org/10.1097/YIC.0000000000000097
  17. Kendall T, Morriss R, Mayo-Wilson E, Marcus E, Guideline Development Group of the National Institute for Health and Care Excellence. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ 2014;349:g5673. https://doi.org/10.1136/bmj.g5673
  18. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30:495-553. https://doi.org/10.1177/0269881116636545
  19. Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINPBD-2017), Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol 2017;20:180-195.
  20. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20:97-170. https://doi.org/10.1111/bdi.12609